SCHEMBL1128084

SCHEMBL1128084

NNC(=O)c1ccccc1C(F)(F)F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.70
GAA P10253 1/20 0.70
PTGS1 P23219 1/20 0.56
KCNK3 O14649 2/20 0.53
KCNK9 Q9NPC2 2/20 0.53
F2R P25116 1/20 0.50
PPIA P62937 1/20 0.50
PTPRC P08575 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CTNNB1 P35222 1/20 0.49
WNT3A P56704 1/20 0.49
CTSD P07339 2/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
RECQL P46063 1/20 0.48
ALDH1A1 P00352 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9830646 0.84 GAA (0.75) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL3964208 0.82 LMNA (0.72) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL108155 0.82 CTSS (0.60) LMNAGAAPTGS1
SCHEMBL16093935 0.82 CTSS (0.60) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL30748278 0.81 LMNA (0.66) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL2494518 0.81 LMNA (0.56) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL2888751 0.81 LMNA (0.66) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL961793 0.81 LMNA (0.66) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL14206037 0.81 LMNA (0.60) LMNAGAAPTGS1KCNK3KCNK9
SCHEMBL6970453 0.81 LMNA (0.70) LMNAGAAPTGS1KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110117235-B Compound with aggregation-induced light emission and mechanochromism characteristics and preparation method and application thereof 江苏萨瑞斯医疗科技有限公司 2022-05-31 CN claimed
CN-110117235-A The compound and its preparation method and application of color shifting properties is caused with aggregation-induced emission and power 江苏萨瑞斯医疗科技有限公司 2019-08-13 CN claimed
CN-109160905-A Using DMF as one step of carbon source construct 2-(4- trifluoromethyl) -1,3,4- oxadiazoles method 桂林理工大学 2019-01-08 CN claimed
CN-103709171-B There is the pyridazine also derivative of [3,4-b] indole framework structure and synthetic method thereof WUHAN UNIVERSITY (CN) 2015-09-16 CN claimed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO claimed
EP-1392219-A4 SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2007-01-24 EP claimed
US-20040186078-A1 Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2004-09-23 US claimed
US-6716859-B2 ANTICANCER AGENTS CYTOVIA, INC. 2004-04-06 US claimed
EP-1392219-A2 SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2004-03-03 EP claimed
US-20030013743-A1 Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2003-01-16 US claimed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP claimed
WO-2002089745-A2 SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2002-11-14 WO claimed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO claimed
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
CN-110505874-B Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 科迪华农业科技有限责任公司 2023-09-26 CN disclosed
WO-2023097386-A1 SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS EUROFARMA LABORATÓRIOS S.A (BR) 2023-06-08 WO disclosed
WO-1999041245-A1 INSECTICIDAL DIHYDRO-OXADIAZINES, -THIADIAZINES AND -TRIAZINES UNIROYAL CHEMICAL COMPANY, INC. (US) 1999-08-19 WO disclosed
EP-0185256-B1 TRIAZOLE DERIVATES, THEIR PREPARATION AND THEIR USE AS PESTICIDES CIBA-GEIGY AG (CH) 1991-01-30 EP disclosed
US-4788210-A PESTICIDES HOFFMANN-LA ROCHE INC. (US) 1988-11-29 US disclosed
EP-0185256-A2 Triazole derivates, their preparation and their use as pesticides CIBA-GEIGY AG (CH) 1986-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186078-A1 Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP2, CASP1, BCL2 LMNA 809/4885GAA 2351/4885PTGS1 643/4885
US-20030013743-A1 Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP2, CASP1, BCL2 LMNA 809/4885GAA 2351/4885PTGS1 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.